AMRX

Dopo l'orario di chiusura: 17.44

Amneal Pharmaceuticals Inc (AMRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1074)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Prossima data di guadagno

Ultimi documenti SEC

AMRX's Discussions on Twitter

Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AMRX Amneal Pharmaceuticals Inc	17.44	6.23B	3.05B	181.32M	186.11M	0.373
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-17	Iniziato	UBS	Buy
2025-12-09	Iniziato	Barclays	Overweight
2025-06-06	Iniziato	Goldman	Buy
2025-02-24	Aggiornamento	JP Morgan	Neutral → Overweight
2024-09-06	Aggiornamento	JP Morgan	Underweight → Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Sector Perform
2021-03-08	Aggiornamento	Goldman	Sell → Buy
2020-12-14	Aggiornamento	Barclays	Equal Weight → Overweight
2020-12-14	Aggiornamento	Guggenheim	Neutral → Buy
2020-07-27	Iniziato	Goldman	Sell
2020-05-12	Aggiornamento	Guggenheim	Sell → Neutral
2019-12-12	Downgrade	Raymond James	Outperform → Mkt Perform
2019-11-12	Downgrade	JP Morgan	Neutral → Underweight
2019-11-07	Downgrade	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-06-11	Iniziato	Barclays	Equal Weight
2019-05-21	Aggiornamento	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Iniziato	SunTrust	Buy
2019-03-08	Downgrade	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Downgrade	SunTrust	Buy → Hold
2018-08-13	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Iniziato	Morgan Stanley	Overweight
2018-06-22	Iniziato	B. Riley FBR, Inc.	Buy

Mostra tutto

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st

Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance

Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats - Yahoo Finance

Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance

US FDA is working with manufacturers to boost estrogen patch supply amid access concerns - Reuters

Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares - scanx.trade

Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st

Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance

J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22 - Moomoo

Amneal builds end-to-end biosimilars capacity in the U.S. - Chain Drug Review

Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich - Sahm

Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - Vinanet

Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire

Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance - Sahm

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance

AMRX Q2 2026 Earnings: Strong EPS Beat Drives 5.1% RallyEarnings Revision Upgrade - vinanet.vn

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media

A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus

Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat

Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan

Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga

Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo

Insider Unloading: Jason Daly Sells $3.77M Worth Of Amneal Pharmaceuticals Shares - Benzinga

Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat

Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat

Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat

Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView

Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan

Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan

AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan

Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan

Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan

Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan

Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan

Amneal Pharmaceuticals (AMRX) Co-CEO gains 6.38M shares in Kashiv acquisition - Stock Titan

Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal - Stock Titan

Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal - Stock Titan

AMRX (AMRX) plans Rule 144 resale of 146,403 equity compensation shares - Stock Titan

Amneal Pharmaceuticals, Inc. SEC Filing (Aug 12, 2026) - Stock Titan

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? - Yahoo Finance

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - Yahoo Finance

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? - Yahoo Finance

Amneal Pharmaceuticals Inc (AMRX) Shares Fall 4.3% -- GF Value S - GuruFocus

Charles Schwab Corp (AMRX): holder files Form 144 for 2.92M-share sale - Stock Titan

Amneal closes $1.1B Kashiv Biosciences acquisition - NJBIZ

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance

Amneal Pharma completes acquisition of Kashiv BioSciences - Pharmabiz.com

California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat

Amneal Pharmaceuticals Adds $350 Million Incremental Term Loan to Fund Kashiv Acquisition - TradingView

Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AMRX